secwatch.observer — SEC 8-K summary
======================================

Issuer:     IMMUNIC, INC. (IMUX)
CIK:        0001280776
Form:       8-K
Filed at:   2024-07-24T23:59:59+00:00
Accession:  0001193805-24-000957
Event type: leadership
Sentiment:  positive
Materiality: 0.45
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunic appoints ex-Roche neuroscience head Skerjanec to board; 150K options granted
--------------------------------------------------------------------------------

- Simona Skerjanec appointed to board effective July 22, 2024 as Class I director until 2027 annual meeting.
- Received inducement grant for 100K shares ($1.46) vesting monthly over 3 years; additional 50K shares vesting over 1 year.
- Board size increased from 7 to 8 members.
- Skerjanec led Roche's Ocrevus commercial launch, generating over $1B in first 10 months.
- Company approaching late-stage readouts for vidofludimus calcium in MS; recently hired ex-Novartis/Biogen COO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1280776/000119380524000957/0001193805-24-000957-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1280776/000119380524000957/e663800_8k-immunic.htm
  HTML page:      https://secwatch.observer/filing/0001193805-24-000957

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer